Survival benefit of adjuvant chemotherapy for patients with poorly differentiated stage IIA colon cancer

Journal of Cancer

Volumn 10, Issue 5, 2019, Pages 1209-1215

  Liu, Qi ^a,b   Luo, Dakui ^a,b   An, Hongyin ^c   Zhang, Sheng ^a,b   Cai, Sanjun ^a,b   Li, Qingguo ^a,b   Li, Xinxiang ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c First Peoples Hospital of Yancheng   (China)

Author keywords

Adjuvant chemotherapy; Stage IIA colon cancer; Tumor grade

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; COLLOID CARCINOMA; COLON ADENOCARCINOMA; COLON CANCER; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOADJUVANT CHEMOTHERAPY; RECURRENCE FREE SURVIVAL; RECURRENT DISEASE; SIGNET RING CARCINOMA;

EID: 85061598300     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.28917     Document Type: Article

References (21)

1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, et al. Colorectal cancer statistics, 2017. Ca Cancer J Clin 2017; 67: 104-17.
2. Jessup JM, Mcginnis LS, Jr SG, Menck HR, Winchester DP. The National Cancer Data Base. Report on colon cancer. Cancer 1996; 78: 918.
3. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. Journal of the National Cancer Institute 2004; 96: 1420.
4. André T, Boni C, Mounedjiboudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. The New England Journal of Medicine 2004; 350: 2343-51.
5. Gray R, Barnwell J, Mcconkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-9.
6. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. Journal of Clinical Oncology 2009; 27: 872-7.
7. Rd BA, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. Journal of Clinical Oncology 2004; 22: 3408.
8. Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2013; 24 Suppl 6: vi64.
9. Babaei M, Balavarca Y, Jansen L, Lemmens V, van Erning FN, van Eycken L, et al. Administration of adjuvant chemotherapy for stage II-III colon cancer patients: An European population-based study. International journal of cancer 2018; 142: 1480-9.
10. Babcock BD, Aljehani MA, Jabo B, Choi AH, Morgan JW, Selleck MJ, et al. High-Risk Stage II Colon Cancer: Not All Risks Are Created Equal. Annals of surgical oncology 2018; 25: 1980-5.
11. Casadaban L, Rauscher G, Aklilu M, Villenes D, Freels S, Maker AV. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer 2016; 122: 3277-87.
12. Kim MK, Won DD, Park SM, Kim T, Kim SR, Oh ST, et al. Effect of Adjuvant Chemotherapy on Stage II Colon Cancer: Analysis of Korean National Data. Cancer research and treatment. 2017; [Epub ahead of print].
13. Matsuda C, Ishiguro M, Teramukai S, Kajiwara Y, Fujii S, Kinugasa Y, et al. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial. European Journal of Cancer 2018; 96: 54-63.
14. O'Connor ES, Greenblatt DY, Loconte NK, Gangnon RE, Liou JI, Heise CP, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. Journal of Clinical Oncology 2011; 29: 3381-8.
15. Verhoeff SR, van Erning FN, Lemmens VE, de Wilt JH, Pruijt JF. Adjuvant chemotherapy is not associated with improved survival for all high risk factors in stage II colon cancer. International Journal of Cancer Journal International Du Cancer 2016; 139: 187-93.
16. Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Woods R, et al. Adjuvant chemotherapy use and outcomes of patients with high‐risk versus low‐risk stage II colon cancer. Cancer 2015; 121: 527-34.
17. Babaei M, Balavarca Y, Jansen L, Lemmens V, van Erning FN, van Eycken L, et al. Administration of adjuvant chemotherapy for stage II-III colon cancer patients: An European population-based study. International journal of cancer 2018; 142: 1480-9.
18. Ochs AM, Wong L, Kakani V, Neerukonda S, Gorske J, Rao A, et al. Expression of Vascular Endothelial Growth Factor and HER2/ in Stage II Colon Cancer and Correlation with Survival. Clinical Colorectal Cancer 2005; 4: 262-7.
19. Lochhead P, Kuchiba A, Yu I, Liao X, Mai Y, Nishihara R, et al. Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication. Journal of the National Cancer Institute 2013; 105: 1151.
20. Staab HJ, Anderer FA, Brummendorf T, Fischer R. Prognostic significance of preoperative carcinoembryonic antigen in stomach and colorectal cancer. Cancer Detection & Prevention 1983; 6: 149.
21. Thirunavukarasu P, Sukumar S, Sathaiah M, Mahan M, Pragatheeshwar KD, Pingpank JF, et al. C-stage in Colon Cancer: Implications of Carcinoembryonic Antigen Biomarker in Staging, Prognosis, and Management. J Natl Cancer Inst 2011; 103: 689-97.